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The study objective was to determine the effects of two treatment regimens on quantities of ceftiofur and
tetracycline resistance genes in feedlot cattle. The two regimens were ceftiofur crystalline-free acid (CCFA)
administered to either one or all steers within a pen and subsequent feeding/not feeding of therapeutic doses
of chlortetracycline. A 26-day randomized controlled field trial was conducted on 176 steers. Real-time PCR
was used to quantify blaCMY-2, blaCTX-M, tet(A), tet(B), and 16S rRNA gene copies/gram of feces from
community DNA. A significant increase in ceftiofur resistance and a decrease in tetracycline resistance
elements were observed among the treatment groups inwhich all steers receivedCCFA treatment, expressed
as gene copies/gram of feces. Subsequent chlortetracycline administration led to rapid expansion of both
ceftiofur and tetracycline resistance gene copies/gram of feces. Our data suggest that chlortetracycline is
contraindicated when attempting to avoid expansion of resistance to critically important third-generation
cephalosporins.
C
ephalosporins are used in both animals and humans to treat a wide variety of bacterial diseases. For the
year 2011, cephalosporins sold or distributed in the United States for use in food-producing animals
amounted to 26,611 kgs1. Ceftiofur, a third-generation cephalosporin, is used in beef cattle to treat bovine
respiratory disease and acute bovine interdigital necrobacillosis. Ceftiofur is classified as a critically important
antimicrobial by theWorldHealthOrganization2. It belongs to the same general class of antibiotics as ceftriaxone,
which has been highly valued in humanmedicine for treating serious and life-threatening infections. Ceftriaxone
is one of the few drugs available to treat invasive salmonellosis in children3,4. Emergence and spread of Salmonella
enterica (non-Typhi), Escherichia coli, and other gut bacteria resistant to third-generation cephalosporins have
been linked by some authors to ceftiofur use in veterinary practice and animal husbandry5–8. Data from the 2010
U.S. National Antimicrobial Resistance Monitoring System (NARMS) indicate that 2.8% of the non-Typhi
Salmonella isolates arising from human clinical cases were resistant both to ceftiofur and ceftriaxone9. At the
same time, 21.5% of non-Typhi Salmonella isolates obtained from food-producing animals at slaughter were
resistant to both ceftiofur and ceftiaxone10. This is a substantial increase when comparedwith 14.5% of non-Typhi
Salmonella animal isolates that were resistant in 2009. The prevalence of ceftriaxone resistance among human
isolates has been observed to be relatively stable since 20049; however, in 2010 ceftriaxone resistance among non-
Typhi Salmonella cattle isolates (22%) was observed to be at its highest since NARMS testing began in 199710. In
response to observed increases in cephalosporin resistance among food animal non-Typhi Salmonella isolates,
and to preserve antibiotic efficacy both in veterinary and human medicine, the U.S. Food and Drug
Administration released an order in April 2012 restricting certain extra-label uses of cephalosporin drugs in
food-producing animals11.
Restricting or banning the use of some less critical antimicrobial classes in animal agriculture may result in
unintended consequences, such as an increase in therapeutic use of antimicrobials that are deemed to be critical
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for human medicine12,13. Strategies to control ceftiofur resistance
need to be designed and tested at the farm level in order to protect
both animal and human health.
The first objective of the study was to evaluate pen-level antimi-
crobial treatment effects as measured by quantifying levels of resist-
ance genes present in cattle feces. Differential ceftiofur treatment was
employed to mimic the practice of housing cattle in their home pen
(post-antimicrobial treatment) versus keeping them in a hospital pen
with all other animals also having recently been treated. The cumu-
lative load of resistant enteric bacteria voided into the feedlot envir-
onment affects the ‘dose’ that other cattle are exposed to through the
fecal-oral route. Models incorporating bacterial metapopulations are
now being used to assess the relative and absolute exposure levels of
cattle to resistant versus susceptible bacteria in agricultural environ-
ments14,15. It has been suggested that readily available, and more
susceptible bacteria, can aid in out-competing the resistant bacterial
populations in the gut of treated animals, thus promoting their recol-
onization with susceptible bacteria16. Although not universally
accepted, many scientists believe that emergent resistance genes
are initially associated with a fitness cost to the host bacterium,
especially soon after the introduction of new drugs to the market17–20.
It was expected that the baseline equilibrium could be reestablished
more quickly in pens where treated and non-treated animals were
housed together than in pens where all animals were treated with a
third-generation cephalosporin. In order to maximize any differ-
ential antimicrobial effects we choose the extreme ratios of treated
versus non-treated animals at 1510 vs 1150, respectively.
The second objective of the study was to evaluate the effect of
feeding chlortetracycline on levels of ceftiofur and tetracycline res-
istance elements detected during the post-therapeutic period of the
two third-generation cephalosporins pen-level regimens described
above. Published papers in the human medical literature have
demonstrated a protective effect of fluoroquinolone as an alternative
intervention against the emergence of cephalosporin resistance21,22.
Our previous work suggested that chlortetracycline in the cattle feed
significantly decreased the prevalence of ceftiofur-resistant E. coli23.
The outcome measure in that study was strictly phenotypic, utilizing
culture-based approaches and measuring the proportion of bacteria
resistant to a panel of 15 antimicrobials (NARMS CMV1AGNF
Gram negative panel, Trek Diagnostics, Cleveland, OH). The total
bacterial load was not quantified, so the effect of chlortetracycline on
the background bacterial population could not be determined. The
current study was designed to evaluate the effects of chlortetracycline
on ceftiofur and tetracycline resistance gene copies, as well as the 16S
rRNA gene copies, using quantitative qPCR assays on community
DNA extracted from the bovine fecal metagenome.
Relying strictly on phenotypic, or even genotypic, data from cul-
tured isolates restricts the focus to a very small subset of the gut
microbiome. Resistance elements are rarely restricted to one genus
(e.g., Escherichia or Salmonella) or even to a family (e.g., Enterobac-
teriaceae). If results from our previous work23 proved to be robust
across the entire metagenome, chlortetracycline would be expected
tominimize the proliferation and accumulation of ceftiofur-resistant
bacteria and their resistance elements in production-animal agricul-
ture settings. Overall, in the present study, samples were evaluated
both at phenotypic24 and genotypic levels, the latter involving both
analysis of fecal bacterial isolates24–26 as well as the broader metagen-
ome. This manuscript focuses on the results obtained from the ana-
lysis of resistance genes present in fecal community DNA and will
compare and contrast those findings with the isolate-based work.
This quantitative study further explores the differential selection
and co-selection of the resistance genes found in the fecal metagen-
ome, based upon pen-level antimicrobial regimens. Several studies,
including this study on E. coli isolates, have demonstrated the phe-
nomenon of differential selection of resistance genes based on chlor-
tetracycline exposure24,26,27. Other studies have likewise reported
associations among various tetracycline and ceftiofur-resistance
genes28–31.
The objective of this study was to investigate the effects of two
treatment strategies: 1) the pen-level effects of the ratio of CCFA-
treated animals housed with untreated animals, and 2) the sub-
sequent pen-level feeding of therapeutic doses of chlortetracycline,
on the levels of cephalosporin and tetracycline resistance gene copies
present in the bovine fecal metgenome. Quantitative real-time PCR
was performed on fecal community DNA to determine the changes
in microbial populations as measured by changes in target gene
copies [blaCMY-2, blaCTX-M, tet(A), tet(B), and 16S rRNA genes]
under the influence of various treatments. The study results were
essentially quantitative; that is, the results are expressed in terms of
absolute resistance gene copies per gram of feces or else standardized
to the 16S rRNA gene copies representing the total bacterial popu-
lation in each gram of feces. Our hypothesis was that both treatment
strategies would help decrease the levels of ceftiofur-resistance ele-
ments in the bovine fecal metagenome.
Results
To initially determine the dynamics of the primary resistance gene of
interest for the full study period, blaCMY-2 and 16S rRNA gene copies
per gram of wet feces were determined from community DNA
extracted from all 2,424 fecal samples obtained from the trial.
There were 176 steers studied in this trial over 26 days. Fecal samples
were collected every other day. Forty samples from 7 animals could
not be collected because the animal either became sick or else died
during the trial. Later, blaCTX-M, tet(A), and tet(B) gene copies per
gram of wet feces were determined only from those 694 fecal samples
obtained from Days 0, 4, 12, and 26 during the trial. These 4 days
represented maximum expected effects of pre-treatment, differential
CCFA-treatment ratios, chlortetracycline administration, and the
post-treatment washout phases, respectively. All community DNA
qPCR assays were run in triplicate.
In our study, depending on the gene, there were as few as zero and
as many as 435 (approximately 21%) missing observations (observa-
tions below the limit of quantification (LOQ) of the qPCR assay). The
blaCMY-2 and 16S rRNA gene quantity datasets derived from all 2,424
community DNA samples (7,272 total observations) had 179 (2.5%)
and zero missing observations, respectively. The data obtained from
a subset of community DNA samples from the representative four
days had 44, 435, 2, and 431 missing observations for blaCMY-2,
blaCTX-M, tet(A), tet(B) genes, respectively, from a total of 2,084
observations. A multiple imputation technique was efficient in
imputing reasonable values to the missing observations in the data-
set. This technique avoided an artificially left-truncated distribution
that is commonly observed with low-copy qPCR since the assay
cannot provide gene quantity values below the LOQ; the LOQ of
the assay being the lowest value estimated among DNA samples as
shown in Figures 1 and 2.
In Figure 1 (A, B), the histograms demonstrate the log10 blaCTX-M
gene quantity distribution from raw and imputed data, respectively,
from the first imputation subdivided by the number of missing
observations (n 5 0, 1, 2, or 3) among the triplicates of any single
community DNA extract (sub graphs: a, b, c, and d). Of the 20
imputations performed and utilized in subsequent multivariate
regression analyses, the histograms shown here are the results of
the first imputation simply to illustrate the distribution of the gene
copies before and after the procedure. Sub graphs a, b, c, and d
represent the distributions of the observations that had: no missing
triplicates, one missing triplicate, two missing triplicates, and all
three missing triplicates, respectively. The arbitrarily assigned non-
zero peak at 21.15 log10 gene copies in the non-imputed histograms
represents those observations that were missing in each category.
The calculated LOQ for the blaCTX-M gene real-time PCR quantifica-
tion assay was 1.82 log10 gene copies per gram. The distribution is
www.nature.com/scientificreports
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therefore left-truncated at this quantification limit (Figure 1 A, sub-
graphs a, b, and c). Figure 1A, subgraph d shows the distribution of
observations that had three missing triplicates. The imputation pro-
cess distributed these observations in a way that yielded many more
observations below the 1.82 log10 gene copies quantification limit
compared with the single or double missing triplicates (Figure 1
and supplementary Table 1). Similarly, raw and imputed gene dis-
tributions alone for the tet(B) gene are shown in Figure 2 A, B. The
limit of quantification for the tet(B) gene was 20.56 log10 gene
copies. Overall, the distribution of missing observations was shifted
much more to the left (i.e., fewer gene copies) as the number of
missing observations among triplicates increased.
From regression analyses, the marginal predicted means of
blaCMY-2 log10 gene copy numbers per gram wet feces alone, stan-
dardized to 16S rRNA gene copy numbers and stratified by the four
treatment groups, are shown in Figure 3A and B. The baseline, Day 0,
predicted mean log10 blaCMY-2 gene copies per gram wet feces (6SE)
for the four treatment groups were 4.29 6 0.12, 4.52 6 0.12, 4.55 6
0.12, and 4.70 6 0.12. The two treatment groups in which only one
steer in a pen received CCFA treatment on Day 0 showed a
non-significant decline (P . 0.05) from Day 0 to Day 4 in the
log10 blaCMY-2 gene copies per gram at the pen level. This was in
contrast to the other two groups where all the steers in a pen received
CCFA treatment (Figure 3, subgraphs A and B) and the gene copies
increased significantly (P , 0.05). As seen on Day 12, chlortetracy-
cline treatment starting after sampling on Day 4 was associated with
further expansion of log10 blaCMY-2 gene copies per gram, regardless
of whether CCFA was administered to one or all eleven steers within
a pen.
Figures 3C, 4A, and 5A show the16S rRNA gene copies alone. The
baseline, Day 0, predicted mean log10 16S rRNA gene copies per
gram 6 SE for the four treatment groups were 10.06 6 0.05, 10.13
6 0.05, 10.10 6 0.05, and 10.01 6 0.05. CCFA administration at
different housing ratios did not lead to any significant changes in the
total 16S rRNA gene copies per gram feces.
Effects of treatments on absolute and standardized ceftiofur-res-
istance (blaCMY-2 and blaCTX-M) gene copy numbers per gram wet
feces for Days 0, 4, 12, and 26 are represented in Figures 4A and B,
respectively. Day 4 illustrates only the effect of CCFA regimen on the
ceftiofur-resistance gene copies. Fecal samples collected from ani-
Figure 1 | Histograms illustrating (A) overall raw distribution of log10 blaCTX-M gene copies per gram feces and, (B) distribution of log10 blaCTX-M gene
copies per gram feces of the imputed estimates of missing observations obtained from a single imputation, subgraphed by the number of missing
observations (a5 0, b5 1, c5 2, d5 3) among the PCR triplicate assays.Note: *represents missing observations arbitrarily assigned a single low non-
zero value.
www.nature.com/scientificreports
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mals in pens in which CCFA was administered to all animals within
the pen (Figure 4A and B, Day 4, depicted by dark navy and maroon
lines) had a greater number of ceftiofur-resistance determinants,
blaCMY-2 and blaCTX-M gene copies per gram, compared with the
other two treatment groups in which CCFA was administered to
only one steer among 11. Day 12 in Figures 4A and B illustrates
the effect of in-feed chlortetracycline on the absolute and standar-
dized ceftiofur-resistance gene copies, respectively. Chlortetracycline
treatment was found to increase both blaCMY-2 and blaCTX-M gene
copies per gram compared with the pens that did not receive chlor-
tetracycline treatment (Figure 4A and B, Day12, depicted by dark
navy and green lines), regardless of the pen-level CCFA treatment
ratio.
The effect of treatments on absolute and standardized tetracycline
resistance [tet(A) and tet(B)] gene copy numbers per gram wet feces
for the four days tested are represented in Figure 5A and B, respect-
ively. Initially, CCFA administered to all steers in a pen significantly
decreased both tet(A) and tet(B) gene copies per gram feces
(Figure 5A and B, Day 4, depicted by dark navy and maroon lines)
at the pen level compared with pens in which CCFA was adminis-
tered to just one steer among 11. More expectedly, there also was a
marked increase in each of the tetracycline resistance tet(A) and
tet(B) gene copies per gram feces following in-feed chlortetracycline
treatment (Figure 5A and B, Day12, depicted by dark navy and green
lines). The dataset, as well as graphs and tables illustrating compar-
ative results from imputed and non-imputed data, have been pro-
vided as part of the supplementary material. Model estimates using
non-imputed data for all five genes also are included in the supple-
mentary material.
Discussion
The hypothesis for this study was based on previous work that sug-
gested that therapeutic doses of chlortetracycline in feed lowered the
proportion of ceftiofur-resistant E. coli isolates found in bovine
feces23. In that study, chlortetracycline appeared to differentially
favor a population of E. coli that were singly, doubly, or even triply
resistant (including to tetracycline) versus those multi-drug resistant
strains in which ceftiofur and tetracycline resistance both were pre-
sent, and always with at least 6 other resistance types23. The results of
that study suggested the intriguing possibility for using chlortetracy-
Figure 2 | Histograms illustrating: (A) overall raw distribution of log10 tet(B) gene copies per gram feces, and (B) distribution of log10 tet(B) gene
copies per gram feces of the imputed estimates of missing observations obtained from a single imputation, subgraphed by the number of missing
observations (a5 0, b5 1, c5 2, d5 3) among the PCR triplicate assays.Note: *represents missing observations arbitrarily assigned a single low non-
zero value.
www.nature.com/scientificreports
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cline as an intervention to control or reduce ceftiofur-resistance
among pens of animals previously treated with ceftiofur, if only in
the short term, by taking advantage of fitness cost differences among
tetracycline-resistant strains.
The present study involved 176 steers. The full study was con-
ducted in two replicates of 88 steers each. Fecal samples were eval-
uated both by non-type-specific (NTS) E. coli culture-based24–26 as
well asmetagenome-based assays. Thismanuscript focuses on results
obtained from an additional analysis of resistance genes copies pre-
sent in the entire fecal metagenome. The NTS E. coli culture-based
study was performed only on the first replicate (n 5 88 steers), while
the metagenome-based assays described in this manuscript involved
both replicates. In the metagenome-based study, 16S rRNA gene
copies were quantified to take into account the effect of treatment
strategies on the total bacterial population.
In the present study, chlortetracycline did not reduce ceftiofur-
resistance in the fecal metagenome; in fact, gene copy numbers of
both blaCMY-2 and blaCTX-M genes significantly increased following
chlortetracycline treatment. There are aspects of this study design
that could have caused discrepancy with the results of Platt et al.
(2008)23. In the present study, either one or else all animals within
each of 8/16 pens received ceftiofur treatment prior to chlortetracy-
Figure 3 | Line graphs illustrating (A) non-standardized log10 blaCMY-2
(B) standardized (as ratio to log10 16S rRNA) log10 blaCMY-2, and (C) log10
16S rRNA gene copies per gram wet feces, by treatment groups and over
days.Dark navy line (with solid square) is for the pens in which CCFA was
administered to all the steers within pens followed by CTC administration
at the pen level; green (with hollow square) is for the pens in which CCFA
was administered to a single steer within the pens followed by CTC
administration at the pen level; maroon line (with solid triangle)
represents pens in which CCFA was administered to all steers within pens
without subsequent CTC administration at the pen level; and orange lines
(with hollow triangle) represents pens in which CCFAwas administered to
a single steer within the pens without subsequent CTC administration at
the pen level. (Data are marginal means with 95% confidence intervals,
represented here as lowess smoothed curves).
Figure 4 | Line graphs illustrating (A) non-standardized log10 blaCTX-M
(short dashed lines), non-standardized log10 blaCMY-2 (solid lines), and
log10 16S rRNA (long dashed lines) gene copies per gram wet feces (B)
standardized (as ratio to log10 16S rRNA) log10 blaCTX-M (short dashed
lines) and log10 blaCMY-2 (solid lines) gene copies per gram wet feces, by
treatment groups and over days. See Figure 3 for treatment groups key.
(Data are marginal means and error bars represent 95% confidence
intervals).
www.nature.com/scientificreports
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cline treatment. Initial ceftiofur exposure among individual animals
might have changed the microbial gut population at the pen level
enough to have modified the effect of CTC26. Importantly, any chlor-
tetracycline effect that would have been expected, unlike the previous
study, would have been observed on the microbial population at
disequilibrium.
The blaCMY-2 gene has previously been quantified in two longit-
udinal trials, one in beef cattle32 and one in dairy cattle33, to evaluate
the effect of ceftiofur treatment. The former trial was an experimental
study in which three different dose regimens of ceftiofur were com-
pared. One of the regimens consisted of a single dose of 6.6 mg/kg;
this was similar to that used in the current study. Alali et al. (2009)32
showed that ceftiofur treatment significantly increased both the stan-
dardized as well as non-standardized log10 blaCMY-2 gene copies per
gram feces; in fact, this is similar to what was observed in our study.
The quantity of blaCMY-2 gene in our study also was comparable to
the earlier feedlot cattle study32; however, the blaCMY-2 gene quant-
ities were lower in the dairy cattle study reported by Boyer et
al.(2012)33. The authors attributed this difference to the likelihood
that feedlot cattle harbor higher blaCMY-2 gene copies as compared to
dairy cattle because of variation in management and environment,
and especially treatment pressures. All three studies recorded a
temporary increase in blaCMY-2 gene copies immediately following
ceftiofur treatment.
We did not observe any significant effects on the 16S rRNA gene
copies following ceftiofur treatment. In the earlier feedlot cattle
study32, the treatment group that received a similar ceftiofur dose
to this study had overall higher predicted mean log1016S rRNA gene
copies per gram when compared to the control group. Results from
both studies indicate that a selective advantage favored expansion of
ceftiofur-resistance elements (and likely bacteria harboring same) as
opposed to a significant reduction in overall bacterial community
DNA following ceftiofur treatment. The dairy cattle study33 did not
report quantification of a bacterial reference gene.
The blaCTX-M gene was detected in E. coli25,26 as reported earlier,
and was also quantified from community DNA samples derived
from feces in this study. For both of the targeted ceftiofur-resistance
genes, blaCMY-2 and blaCTX-M gene copies per gram feces significantly
increased in treatment groups where all animals were administered
CCFA compared with the pens in which only one animal received
CCFA treatment. The short-term selection of blaCMY-2 gene copies
following CCFA administration has been previously documented, as
mentioned before32,33. However, this is the first study to quantify the
blaCTX-M gene in feedlot cattle in the United States. This gene has
been noticeably absent from North American agriculture for some
time now.
The quantities of tetracycline genes tet(A) and tet(B) significantly
decreased on Day 4 in treatment pens where all animals were admi-
nistered CCFA as compared to the pens where only one animal
received CCFA treatment. Several phenotypic studies on E. coli have
recorded that all ceftiofur-resistant isolates were found to be co-res-
istant to tetracycline5,23,34. Therefore, although the decrease in copies
per gram wet feces of both tetracycline genes from community DNA
was unexpected, it is readily explainable. First, E. coli bacteria consti-
tute a small fraction of the entire microbial community; that is, the gut
flora comprises both culturable and non-culturable organisms that
may or may not carry ceftiofur and tetracycline determinants together
on one plasmid. Second, even though those E. coli that remain follow-
ing ceftiofur treatment are resistant both to ceftiofur and tetracycline,
those bacteria that are resistant only to tetracycline do not survive, or
else are suppressed. The complexity of the co-selection or co-resistance
mechanisms has been discussed by Doyle et al. (2013)35. Microbial
populations, along with their constituent organisms, may evolve dif-
ferently under specific selection pressures in different niches, depend-
ing on both the complexity of the niches and the selection pressure,
particularly if the starting bacterial population is not exactly the same.
Competitive bacterial interactions play a critical role in niches such as
the host gut that harbor large numbers of varied microbes35.
The blaCTX-M gene in the culture-based study was always found to
be harbored on an IncN plasmid among the 1,050 E. coli isolates
examined from the 88 first replicate animals25. This plasmid was
shown to be self-transmissible without conferring any additional
fitness cost to the recipient E. coli25. This indicates the presence of
E. coli (and likely other Gram-negative bacteria) that harbor plas-
mids which possess resistance determinants directed towards beta-
lactams (including third-generation cephalosporins) alone; in
contrast, the blaCMY-2 gene in U.S. cattle has previously almost
always been reported to be associated with multiple drug resistance
and located on an IncA/C plasmid35,36. Furthermore, E. coli isolates
derived from 29 out of 88 first replicate study animals tested positive
for the blaCTX-M gene25. Our metagenome-based assay quantified
blaCTX-M gene copies from 87 out of 88 animals from at least one
community DNA sample. All DNA samples derived from 12 animals
had measurable blaCTX-M gene copies (greater than the threshold
limit of the qPCR assay). Of 1050 community DNA samples from
the first replicate, 760 hadmeasurable blaCTX-M gene copies (data not
shown). These results clearly indicate a higher sensitivity of meta-
genome-based assays than culture-based approaches alone.
Figure 5 | Line graphs illustrating (A) non-standardized log10 tet(B)
(short dashed lines), non-standardized log10 tet(A) (solid lines), and log10
16S rRNA (long dashed lines) gene copies per gram wet feces (B)
standardized (as ratio to log10 16S rRNA) log10 tet(B) (short dashed lines)
and log10 tet(A) (solid lines) gene copies per gramwet feces, by treatment
groups and over days. See Figure 3 for treatment groups key. (Data are
marginal means and error bars represent 95% confidence intervals).
www.nature.com/scientificreports
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Distinct differences were observed between the E. coli (culture-
based assay) results24,26 and the gene quantification results obtained
in this study. The qPCR results from community DNA indicated an
increase in both blaCMY-2 and blaCTX-M gene copies per gram wet
feces following chlortetracycline treatment. This runs counter to the
results obtained from E. coli isolates in which the blaCMY-2 gene was
differentially favored over the blaCTX-M gene when chlortetracycline
was fed26. Similarly, tet(A) and tet(B) gene copies per gram wet feces
significantly decreased on Day 4; this was in direct contrast to an
observed increase in the proportion of E. coli isolates harboring
tet(A) and tet(B) following ceftiofur treatment24.
These results clearly indicate the bias that can be introduced if
conclusions regarding microbial populations are based solely on
particular culturable organisms. There is a huge unculturable micro-
bial population that might well be expected to behave differently
under similar selective pressures. Furthermore, it has been indicated
before that the bacterial cells can also lose the entire plasmid or parts
of the plasmid carrying resistance determinants, or the resistance
genes may not be expressed under culturing stress32,37. Therefore,
results from specific culturable organisms may incorrectly estimate
the presence and quantity of target resistance genes among the gut
flora. The results frommetagenome-based assays also have their own
limitations; for example, different bacterial species may have mul-
tiple and variable amounts of target gene copies per bacterial cell
(relative abundance)32,38. The metagenome-based assay gives
information about the overall target gene load in community
DNA, but information about variations in specific bacterial species
carrying target genes is not provided from this community DNA-
based assay. At present, most antimicrobial resistance monitoring
and surveillance systems across theworld test isolates and/or samples
for antimicrobial resistance by using culture-based methods.
Extrapolating the results obtained from specific culturable organisms
(e.g. E. coli, Salmonella, or Campylobacter) to the entire microbial
community may not be valid. This can heavily influence the policies
formulated by regulatory bodies to control antimicrobial resistance
in humans and animals. Therefore, ametagenome-based component
should be considered as one part of a more holistic monitoring
system to identify when contradictory or paradoxical results are seen,
especially to avoid any such biases when making important policy
decisions.
A multiple imputation procedure, a simulation-based method,
was used to deal with missing data in this study. Several plausible
imputed datasets are created in this procedure and results from each
are combined in subsequent regression analyses by taking the aver-
age over the distribution of these missing data. This technique per-
mits accounting for the uncertainty linked with the missing data39.
The imputed datasets for missing values were sampled from a pre-
dictive distribution which was based on observed data. Therefore,
this procedure is essentially based on a Bayesian approach39. This
procedure has been suggested to produce less-biased estimates and
more accurate standard errors as compared to other approaches such
as single imputation, mean imputation, and complete case analysis40.
According to one paper41 a relative efficiency of 99% could be
achieved by utilizing 20 imputations when 20% of the observations
are missing. Another study proposed that multiple imputation tech-
niques did not improve a linear mixed model when missing data
represented up to 40% of the sample set42. However, the authors
acknowledged that a multiple imputation procedure may be useful
if such models included relevant predictor variables, which were not
included in their linear mixed models but were included in ours.
Multiple imputation procedures should utilize known covariates that
are believed to be associated with the missing values43.
The maximum missing observations in the study were approxi-
mately 21% for any given gene. Twenty imputations were utilized to
get reasonable estimates of all missing observations. We based our
imputationmodel on unique animal identifier (which comprised pen
as well as CCFA and CTC treatment status), sampling day, and the
number of observations missing among the triplicate of each sample
(i.e., 1, 2, or all 3 triplicates were missing). The number of missing
observations among the triplicates was considered as an important
predictor, similar to the previous dairy study that imputed missing
quantitative real-time PCR data44. The histograms as well as the
supplementary Table 1 resulting from the imputed datasets, dem-
onstrating log10 distributions of gene copies per wet gram feces, and
based on the number of missing observations per triplicate, reveal
that the distribution of missing observations shifts towards the left
(including additional imputed observations at lower gene copies) as
the number of missing values among triplicates increases.
Observations in which all three data points among the triplicates
were missing were more likely to be assigned a lower value and also
a value below the assay limit of quantification when contrasted with
observations with either double or single missing values among the
triplicates.Multiple imputation is a useful tool to handlemissing data
and obtain a valid inference from parametric statistical models sim-
ilar to the ones used in this study, and whose assumptions depend on
the integrity of underlying distributions. It is an effective procedure
to analyze qPCR data, which often have moderate levels of missing
values.
Overall, our study results indicate that chlortetracycline should
not be used in an attempt to control ceftiofur-resistance following
treatment with a cephalosporin; rather, such an approach would
appear to be misguided at best. Chlortetracycline treatment led to
significant expansion of both blaCMY-2 and blaCTX-M genes copies per
gram wet feces, especially in cattle pens where all animals were prev-
iously exposed to ceftiofur. Pen-level ceftiofur-resistance elements
were present in lower numbers in pens where just one CCFA treated
animal was co-housed with many more non-treated pen-mates.
Further studies with mixing at differing treatment ratios should be
conducted in order to establish the threshold of the co-mingling
effect on levels of antimicrobial resistance. In addition, distinct dif-
ferences were observed when comparing culture-based results
reported elsewhere24,26 and the metagenome-based results obtained
herein; this warrants further investigation as current worldwide anti-
microbial resistance monitoring and surveillance systems tend to be
based solely on culture-based approaches. Such approaches may
provide a biased picture of the changes occurring in the microbiome
because they depend largely on the organisms being observed. The
incorporation of gene quantification and other metagenome-based
approaches in surveillance systemsmay dramatically increase amore
holistic understanding in the sphere of antimicrobial resistance.
Methods
Study design. Based on the animal study location and relevant institutional oversight
of the co-investigators’ roles, the protocols and procedures were approved by the
Clinical Research Review Committee at Texas A&M University (CRRC # 09-35) and
the Amarillo-Area Cooperative Research, Education, and Extension Triangle Animal
Care and Use Committee (Protocol No. 2008-07). An Institutional Biosafety
Committee approval was in place at Kansas State University (IBC No. 794) where the
laboratory analyses took place. Bovine fecal samples were obtained from feeder cattle
in a 26-day field trial. The randomized controlled longitudinal study was conducted
in accordance with the approved protocols on 176 steers. The steers were housed in
two replicates of 88 steers each. For each replicate, steers were assigned to eight pens of
11 steers such that the average pen weights were similar. A total of four treatment
groups resulted from the random allocation of two treatment strategies in a complete
two-way full factorial manner. The two strategies were: 1) differential pen-level CCFA
treatment ratios (Mix) and, 2) subsequent pen-level chlortetracycline treatment
(CTC). Pen-level CCFA treatment ratios (Mix) referred to whether long acting CCFA
(ExcedeH, Zoetis Animal Health, Florham Park, NJ, U.S.A.) was administered to
either one or else all 11 animals within pens. Pen-level CTC treatment (AureomycinH,
pre-mix complex equivalent to 220.5 g of chlortetracycline/kg, Alpharma,
Bridgewater, NJ) referred to whether all cattle in a pen received chlortetracycline
treatment top-dressed on feed, subsequent to the CCFA treatment. The study day
(Day) was considered as a third factor in the statistical models. This accounted for the
effect of day of trial on the quantities of resistance genes detected in feces from the
steers.
OnDay 0, a single dose of CCFA treatment was injected subcutaneously at the base
of the ear in all steers in eight of the 16 pens at a dose rate of 6.6 mg/kg. Subsequently,
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all animals in four of these eight pens received chlortetracycline treatment at the
labeled dose rate of 22 mg/kg body weight administered during three separate 5-day
periods (with a one-day break in between). Top-dressing occurred after the morning
feed was delivered starting on Day 4. In the remaining eight pens, only one steer
among 11 pen-mates within the pen received CCFA treatment. Subsequent chlorte-
tracycline treatment among these eight pens was likewise given to all animals in just
four of the pens (Table 1).
Fecal grab samples were collected per rectum every other day fromDay 0 to Day 26,
after restraining the animals in a squeeze chute; in total, 2,424 samples were collected.
For each fecal sample, two 5 ml vials were filled to the 4 ml level with fresh feces.
These fecal samples were stored at 270uC for further genotypic analysis.
Community DNA extraction. Total community DNA was extracted from 200 mg
feces via the QIAampDNA StoolMini KitTM (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. The extraction was performed in the QIAcube robotTM
(Qiagen, Valencia, CA). The quality and concentration of DNA samples were
determined via NanoDropH ND-1000 UV-Vis Spectrophotometer (NanoDrop
Technologies,Wilmington, DE). TheseDNA samples were used for further genotypic
quantification.
Genotypic quantification of target genes in community DNA. Gene copies/gram
wet feces of blaCMY-2, blaCTX-M, tet(A), tet(B), and 16S rRNA genes were determined
in fecal community DNA using quantitative real time PCR (qPCR). All four
resistance gene copy numbers were standardized to the 16S rRNA gene, used as the
reference gene in this study. The PCR plates were set up using an automated robot
(QIAgilityTM, Qiagen, Valencia, CA). The fecal community DNA was used directly as
a template in qPCR reactions for quantification of the genes using a Stratagene
Mx3005PTM real-time qPCR system (Agilent Technologies, La Jolla, CA). The real
time qPCR reactions for blaCMY-2 and 16S rRNA genes were adapted from a
technique previously described by Alali et al. (2009)32; qPCR reactions for tet(A), and
tet(B) genes were adapted from Fan et al. (2007)45; and qPCR reactions for blaCTX-M
were adapted from Cottell et al. (2013)25. These blaCTX-M primers targeted all five
major CTX-M groups (1, 2, 8, 9, and 25). The variants considered for blaCTX-M primer
design were derived fromNovais et al. (2010)46. All 2,424 samples were quantified for
blaCMY-2 and 16S rRNA genes per gram; however, only samples from Days 0, 4, 12,
and 26 from both replicates were chosen for tet(A), tet(B), and blaCTX-M gene
quantification. All community DNA qPCR assays were run in triplicate. Primers set
details are listed in Table 2.
Controls.An E. coli strain (M1) was used as the positive control for the blaCMY-2 and
16S rRNA gene. It was earlier obtained from theUniversity of Illinois, Chicago47. XL1-
Blue E. coli strain (Agilent Technologies, Santa Clara, CA) and E. coli ATCC 47042
were used as the positive controls for tet(A) and tet(B) genes, respectively. The
blaCTX-M positive control was an E. coli isolate internal control strain obtained from
this study, which was positive on PCR with the specific primers. The PCR product
from this strain was sequenced for confirmation of the blaCTX-M-32 gene and has been
published elsewhere25. These controls were also used for the generation of template
for the standard curve. Two negative controls were run with each 96-well PCR plate.
One was the no-template control and the other had DNA-free water as a template.
Standard curve template generation. Template for the standard curve for two genes
(blaCMY-2 and 16S rRNA)was generated with a PCR reaction utilizing the broad range
primers in a total volume of 22 ml. Each reaction contained 12.5 ml of 2 3 Brilliant II
SYBRHGreen QPCRMaster Mix (Agilent Technologies, Santa Clara, CA), 4.75 ml of
nuclease free water (Qiagen, Valencia, CA), 1 ml of each primer (135 nM and 185 nM
for blaCMY-2 and 16S rRNA genes, respectively), 0.75 ml of reference dye (30 nM), and
2 ml of the DNA extracted fromM1 strain (positive control). The thermal profile for
amplification was similar to as described byAlali et al. (2009)32. Both tet(A) and tet(B)
gene PCR reactions were run in a total volume of 20 ml. Each reaction contained 10 ml
of 2 3 Brilliant II SYBRH Green QPCR Master Mix, 6.25 ml of nuclease free water,
0.5 ml of each primer (556 nM), 0.75 ml of reference dye (30 nM), and 2 ml of the
positive control DNA [XL1-Blue E. coli strain-tet(A) and E. coliATCC 47042-tet(B)].
The thermal profile for amplification for both tet genes was 95uC for 10 minutes, 45
cycles of 95uC for 15 seconds, 60uC for 30 seconds, and 72uC for 28 seconds. The
blaCTX-M gene PCR reactions were run in a total volume of 25 ml. Each reaction
contained 12.5 ml of 2 3 Brilliant SYBRH Green II QPCR Master Mix, 9.5 ml of
nuclease free water, 0.625 ml of each primer (260 nM), 0.75 ml of reference dye
(30 nM), and 1 ml of the positive control DNA. The thermal profile of these reactions
was 94uC for 5 minutes, 40 cycles of 94uC for 1 minute, 57uC for 1 minute, and 72uC
for 1minute. Thermal profiles for all gene targets ended with one last cycle to obtain a
Table 1 | Schematic representation of the study design
176 steers; 16 pens; 4 treatment groups
Group 1 Group 2 Group 3 Group 4
4 pens, 11 steers each 4 pens, 11 steers each 4 pens, 11 steers each 4 pens, 11 steers each
- All 11 steers receive CCFA;
6.6 mg/kg once on Day 0
-All 11 steers receive CCFA;
6.6 mg/kg once on Day 0
-One among 11 steers receive
CCFA; 6.6 mg/kg once on Day 0
-One among 11 steers receive
CCFA; 6.6 mg/kg once on Day 0
- CTC 22 mg/kg; 3 treatment
regimens- 5 days each starting
Day 4
-No CTC Treatment -CTC 22 mg/kg; 3 treatment
regimens- 5 days each starting Day 4
-No CTC treatment
The two interventions were assigned in a two-way full factorial manner. Number of pens assigned to each treatment and number of animals within each of the pens are shown above.
Table 2 | Primers used for PCR reactions
Gene name Primer Primer Sequence Expected Product Size (bp) GenBank Accession no.*
blaCMY-2 585F 59- CAG ACG CGT CCT GCA ACC ATT AAA -39 454a,1 AB212086
1038R 59- TAC GTA GCT GCC AAA TCC ACC AGT -39
675F 59- AGG GAA GCC CGT ACA CGT T -39 64a,2
738R 59- GCT GGA TTT CAC GCC ATA GG -39
blaCTX-M CTX-M(F) 59 -ATGTGCAGYACCAGTAA- 39 536b AY143430_CTX-M-24
CTX-M(R) 59 -CCGCTGCCGGTYTTATC- 39
tet(A) tet(A)(F) 59 -GCTACATCCTGCTTGCCTTC- 39 210c X61367
tet(A)(R) 59 -CATAGATCGCCGTGAAGAGG- 39
tet(B) tet(B)(F) 59 -TTGGTTAGGGGCAAGTTTTG- 39 659c J01830
tet(B)(R) 59 -GTAATGGGCCAATAACACCG- 39
16S rRNA 1056F 59 - AAT GTT GGG TTA AGT CCC GCA ACG - 39 400a,1 EU014689
1456R 59 - ATG ATC ACA AAG TGG TAA GCG CCC - 39
P201 59- GAG GAA GGI GIG GAI GAC GT - 39 216d,2
P1370 59 - AGI CCC GIG AAC GTA TTC AC - 39
aPrimer set used are from Alali et al.32
bPrimer set used are from Cottell et al.25
cPrimer set used are from Ng et al.49
dPrimer set used are from Steinman et al.50
1Broad range primers to generate template for the standard curve.
2Narrow range primers for sample quantification.
*Sequence used for primer design.
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dissociation curve, which consisted of 95uC for 1 minute, 55uC for 30 seconds, and
95uC for 30 seconds.
These PCR products were purified using a DNA purification kit (Promega
Corporation, Madison, WI). This purified DNA was used as the template for gen-
erating standard curves, after determining its concentration via NanoDropH ND-
1000 UV-Vis Spectrophotometer (NanoDrop Technologies, Wilmington, DE) at
wavelengths of 260 and 280 nm. The quantities of target gene copies ml21 for standard
curve generation were determined under consideration of themolecular weight of the
amplicons, weight of one mole of base pairs, and concentration of PCR product.
Quantification of target genes in unknown samples. Narrow range primers for
blaCMY-2 and 16S rRNA genes and the same set of primers for the tet(A), tet(B), and
blaCTX-M resistance genes were used to quantify the gene copies in the unknown
samples along with the standard curve. Standard curves used the 10 fold serial
dilution of the 2 ml purified PCR products described above (with known number of
gene copies) to 18 ml of nuclease-free water to a minimum concentration of 100 for
blaCMY-2, blaCTX-M, and both tetracycline genes, and aminimum concentration of 103
for 16S rRNA gene. The lowest five concentrations were used to build each standard
curve. All reactions, including standards, were run in triplicate. The reaction mixture
composition was same as that used for the standard curve template generation for all
respective genes. The thermal profile for amplification for the blaCMY-2 gene was 95uC
for 10minutes, 40 cycles of 95uC for 10 seconds, 52uC for 30 seconds, and 79uC for 17
seconds. Likewise, the thermal profile for the16S rRNA gene was 94uC for 10minutes,
40 cycles of 94uC for 2minutes, 60uC for 1minute, and 72uC for 17 seconds. Thermal
profiles for the tet(A), tet(B), and blaCTX-M resistance genes were the same as for the
standard curve template generation. Dissociation curves were run with every plate to
examine the specificity of the amplifications.
Statistical analysis. The gene copy number estimates were derived from either 1 or
2 ml of the sample community DNA, depending on the gene being quantified. The
gene quantities per microliter were back calculated to estimate gene copies per gram
wet feces. Non-standardized blaCMY-2, blaCTX-M, tet(A), and tet(B) gene copies per
gram wet feces and the quantities obtained by standardizing them in a ratio with the
16S rRNA gene were used for the outcomes. All standardized and non-standardized
quantities were logarithmically transformed to log base 10 for use as a dependent
variable in both multiple imputation and mixed (fixed and random effect) linear
regression models.
A missing value was recorded in instances where qPCR amplification was below
the quantification limit of the assay, or else was estimated below the threshold limit
determined by the assay. These observations were considered missing; however, they
were initially assigned an arbitrary very low non-zero value so that logarithmic
transformation was possible for graphical purposes. Many of these observations were
expected to have values more than zero but below the limit of quantification of the
assay utilized. Estimates of missing values were imputed using a multiple imputation
procedure in STATAH SE Release 12.1 (STATA Corp., College Station, TX). A
multiple regression method was utilized for the imputation process. Our imputation
model was based on the unique animal id (repeats within animal), sampling day, and
the number of observations missing among the triplicates from each sample (i.e., 0, 1,
2 or all 3 triplicates were missing). Twenty imputations were performed to reduce the
sampling variability from the imputation process41,48. The descriptive statistics
(supplementary Table S1) from the first five imputed datasets (out of 20 datasets)
were compared to the non-imputed dataset.
Before deciding to utilize the linear regression-based imputation methods, two
other imputation techniques (truncated regression and interval censored regression,
with upper limit cutoff values of 3 log10 and 7 log10 gene copies per gram, respectively)
were explored. The distribution of the estimates of the imputed values for blaCTX-M
gene, and the comparative descriptive statistics for blaCTX-M and tet(B) from all three
imputation techniques are provided as supplementary Figure S1 and supplementary
Table S2, respectively. Additionally, results of themain linear regressionmodels, both
before and after imputation, were compared to examine and rule out any biases that
might introduced during the imputation procedure. Supplementary Figure S2
represents the graphical output of marginal predicted means obtained from the non-
imputed dataset, where missing observations were substituted with low non-zero
values for each of the 5 genes (blaCMY-2, blaCTX-M, tet(A), tet(B), and 16s rRNA genes).
Supplementary Table S3 facilitates direct comparison of the predicted marginal
means obtained from regression analyses using non-imputed and imputed data.
To determine the effect of treatments on gene quantities, a multi-level mixed linear
model was utilized on the datasets following imputation. The three explanatory
variables tested in the model were pen-level CCFA treatment (ratio at which CCFA
was administered within a pen), pen-level CTC administration, and the sampling day
(period). The relationships among the outcome and the explanatory variables were
assessed using the mixed linear regression model with three-way full factorial design
of the three explanatory variables (fixed effects) in STATAH SE Release 12.1 (STATA
Corp., College Station, TX). The models accounted for pen level dependencies as
random effects; however, due to convergence issues the animal level dependencies
could not be accounted for within the models. Because animals are nested within
pens/treatments, this is perhaps not surprising.
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